Sally Susman net worth and biography

Sally Susman Biography and Net Worth

Insider of Pfizer
Sally Susman is Executive Vice President and Chief Corporate Affairs Officer at Pfizer. She is vice chair of the Pfizer Foundation and co-chair of Pfizer’s Political Action Committee.

Sally leads engagement with all of Pfizer’s external stakeholders overseeing communications, corporate responsibility, global policy, government relations, investor relations and patient advocacy. Before joining Pfizer in 2007, Sally held several senior communications and government relations roles at Estée Lauder Companies and the American Express Company. Earlier in her career, she spent eight years in government service focused on international trade issues.

Sally serves on the board of WPP plc, a world leader in advertising and marketing based in the U.K., and as co-chair of the board of The International Rescue Committee. She is also a member of the Council on Foreign Relations.

What is Sally Susman's net worth?

The estimated net worth of Sally Susman is at least $6.80 million as of July 20th, 2018. Ms. Susman owns 155,377 shares of Pfizer stock worth more than $6,799,298 as of October 1st. This net worth approximation does not reflect any other investments that Ms. Susman may own. Learn More about Sally Susman's net worth.

How do I contact Sally Susman?

The corporate mailing address for Ms. Susman and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Sally Susman's contact information.

Has Sally Susman been buying or selling shares of Pfizer?

Sally Susman has not been actively trading shares of Pfizer within the last three months. Most recently, Sally Susman sold 40,381 shares of the business's stock in a transaction on Friday, July 20th. The shares were sold at an average price of $37.22, for a transaction totalling $1,502,980.82. Following the completion of the sale, the insider now directly owns 155,377 shares of the company's stock, valued at $5,783,131.94. Learn More on Sally Susman's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 272,486 shares worth more than $14,002,996.88. The most recent insider tranaction occured on June, 7th when SVP Jennifer B Damico sold 4,218 shares worth more than $227,603.28. Insiders at Pfizer own 0.1 % of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 6/7/2022.

Sally Susman Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/20/2018Sell40,381$37.22$1,502,980.82155,377View SEC Filing Icon  
2/27/2018Sell33,368$37.03$1,235,617.04191,505View SEC Filing Icon  
9/12/2017Sell38,230$35.00$1,338,050.00145,649View SEC Filing Icon  
5/5/2016Sell76,116$33.75$2,568,915.00195,951View SEC Filing Icon  
3/12/2015Sell46,179$34.00$1,570,086.00View SEC Filing Icon  
3/4/2014Sell67,585$32.59$2,202,595.15173,637View SEC Filing Icon  
See Full Table

Sally Susman Buying and Selling Activity at Pfizer

This chart shows Sally Susman's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $43.76
Low: $43.73
High: $44.61

50 Day Range

MA: $47.54
Low: $43.76
High: $52.30

2 Week Range

Now: $43.76
Low: $40.94
High: $61.71

Volume

22,870,907 shs

Average Volume

25,401,170 shs

Market Capitalization

$245.60 billion

P/E Ratio

8.56

Dividend Yield

3.62%

Beta

0.7